The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
Other factors such as state-level laws, insurance networks, or cultural preferences likely explain the remaining variance in brand preference across US counties, according to researchers Rachel D. Melamed, PhD, and Andrey Rzhetsky, PhD, of the University of Chicago. They concluded that a “patchwork” of contrasting medication cultures is in place across the nation, showing “geographically separated sub-Americas” that demonstrate the influences of racial composition, state-level healthcare laws, and wealth.
Their findings are based on an analysis of Truven MarketScan medical claims data covering more than 150 million individuals (nearly half the country’s population), followed for up to 10 years (2003-2013). The authors focused on comparing prescription rates of the 598 most highly prescribed drugs in more than 2300 US counties. The data contain a total of approximately 36 million patient-years.
Among the study’s findings are the following:
The study was funded by the DARPA Big Mechanism program and by National Institutes of Health grants.
Reference
Melamed RD, Rzhetsky A. Patchwork of contrasting medication cultures across the USA. Nature Communications.2018;9:4022. doi: 10.1038/s41467-018-06205-1.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.